Alnylam Pharmaceuticals (ALNY) EBT Margin (2009 - 2026)
Alnylam Pharmaceuticals (ALNY) posted EBT Margin of 18.99% for Q1 2026, up 141.51% on a QoQ basis from 7.86% in Q4 2025, and up 1939.0% year-over-year from 0.93% in Q1 2025.
Alnylam Pharmaceuticals (ALNY) EBT Margin (2009 - 2026) Analysis & Trends
Alnylam Pharmaceuticals' EBT Margin history runs 18 years deep, the most recent figure standing at 18.99% for Q1 2026.
- Quarterly EBT Margin rose 1939.0% year-over-year to 18.99% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 12.9% (up 2637.0% YoY) and the FY2025 annual result came in at 8.7%, up 2549.0% from the prior year.
- EBT Margin was 18.99% for Q1 2026 at Alnylam Pharmaceuticals, up from 7.86% in the prior quarter.
- Across five years, EBT Margin topped out at 22.46% in Q3 2025 and bottomed at 153.59% in Q3 2022.
- A 5-year average of 36.8% and a median of 21.69% in 2024 frame the typical range for EBT Margin.
- Annual changes were most pronounced in 2022 — EBT Margin sank 4474 bps — and 2023, when it soared 17367 bps.
- Alnylam Pharmaceuticals' EBT Margin stood at 61.79% in 2022, then jumped by 49 bps to 31.31% in 2023, then retreated by 4 bps to 32.7% in 2024, then surged by 124 bps to 7.86% in 2025, then jumped by 142 bps to 18.99% in 2026.
- Business Quant data shows ALNY's EBT Margin at 18.99% in Q1 2026, 7.86% in Q4 2025, and 22.46% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 17.13% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 41.95% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.05% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 34.77% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Alnylam Pharmaceuticals | 35.71 Bn | 32.70 Bn | 959.66 Mn | 18.99% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 18.99% |
| Dec 31, 2025 | 7.86% |
| Sep 30, 2025 | 22.46% |
| Jun 30, 2025 | -4.57% |
| Mar 31, 2025 | -0.40% |
| Dec 31, 2024 | -32.70% |
| Sep 30, 2024 | -21.69% |
| Jun 30, 2024 | -1.69% |
| Mar 31, 2024 | -12.86% |
| Dec 31, 2023 | -31.31% |
| Sep 30, 2023 | 20.08% |
| Jun 30, 2023 | -86.03% |
| Mar 31, 2023 | -53.98% |
| Dec 31, 2022 | -61.79% |
| Sep 30, 2022 | -153.59% |
| Jun 30, 2022 | -122.18% |
| Mar 31, 2022 | -112.24% |
| Dec 31, 2021 | -100.68% |
| Sep 30, 2021 | -108.85% |
| Jun 30, 2021 | -85.39% |